Voyager Therapeutics Stock Analysis, Valuation (NASDAQ:VYGR)

Add to My Stocks
$19.78 $0.84 (4.44%) VYGR stock closing price May 24, 2018 (Closing)
Watch Robo Advisor Video of VYGR Stock Analysis
Voyager Therapeutics
Updated on : May 24, 2018
previous close
VYGR 19.8 (0%)
S&P 500 2727.8 (0%)
Closing Price On: May 24, 2018
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Generic Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2018-Q1
$million
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
-784.1%
Sector Average:
-12.2%
5 Quarter Net Profit
Net Margins
2018-Q1
%
LTM Margin
Cash Flow
Operating cash flow:
$48.6M
Net Income:
-$19.9M
PROS      CONS
FCF Margin
Recent Growth
Operating Margins
Net Margins
ROE
PE Valuation
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
VYGR PS :
65.3
Industry PS :
6.5
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Equity:
-67.8%
Free Cash Flow Margin:
5000%
Double Tap To Exit Full Screen
0:00
/

Voyager Therapeutics Stock Analysis

11 5 2

View the Voyager Therapeutics stock analysis video on Amigobulls. This is our analyst opinion covering the buy and sell arguments for VYGR stock.

Note: Amigobulls stock rating is our opinion based on the historical performance of the company's fundamentals. It is not indicative of the future performance of the stock.

Voyager Therapeutics Inc Stock Rating 1.7/5

Amigobulls VYGR stock analysis relies on business fundamentals such as Voyager Therapeutics revenue growth, profits and return on equity measures from the latest quarter 2018 Q1 earnings. Voyager Therapeutics valuation forms a crucial part of our stock analysis. Based on a company's historical fundamentals we arrive at Voyager Therapeutics stock rating which is indicative of the company's financial performance.

Should you buy VYGR stock?

  • The company has a healthy free cash flow margin of 5000%.

Should you sell VYGR stock?

  • Voyager Therapeutics revenue saw a decline of -35.6% YoY in 2018 Q1.
  • Over the last twelve months, Voyager Therapeutics posted an average operating loss margin of -784.1%.
  • Over the last 12 months, Voyager Therapeutics had an average Net loss of -768.5%.
  • The lack of profits renders the PE ratio useless for VYGR stock.
  • VYGR stock is trading at a PS multiple of 65.3, which is a negative when compared to the Medical-Generic Drugs industry average multiple of 6.5.
  • Voyager Therapeutics has a negative return on equity of -67.8%. This indicates that the firm is inefficient at generating profits.

Voyager Therapeutics Related Company Stock Videos

Comments on this video and Voyager Therapeutics stock

Investors can use Amigobulls Voyager Therapeutics stock analysis as a tool to arrive at accurate conclusions regarding financial health of the company and its valuation. Company's fundamentals remain one of the key driver of VYGR stock and helps investors in making good buy and sell decision.

While doing a study of the company financials, Voyager Therapeutics revenue growth and profit or net income are two main metrics which help in identifying whether VYGR stock is overvalued or undervalued. Technical analysis comes in handy to check whether the market sentiment is in line with the fundamental picture of the company.